156 related articles for article (PubMed ID: 20862594)
21. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
22. Methyl-branched fatty acids, inhibitors of enoyl-ACP reductase with antibacterial activity from Streptomyces sp. A251.
Zheng CJ; Sohn MJ; Chi SW; Kim WG
J Microbiol Biotechnol; 2010 May; 20(5):875-80. PubMed ID: 20519910
[TBL] [Abstract][Full Text] [Related]
23. Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase.
Kumar A; Siddiqi MI
J Mol Model; 2010 May; 16(5):877-93. PubMed ID: 19779936
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
25. Molecular modeling studies, synthesis, and biological evaluation of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR) inhibitors.
Morde VA; Shaikh MS; Pissurlenkar RR; Coutinho EC
Mol Divers; 2009 Nov; 13(4):501-17. PubMed ID: 19347595
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.
More UA; Joshi SD; Aminabhavi TM; Gadad AK; Nadagouda MN; Kulkarni VH
Eur J Med Chem; 2014 Jan; 71():199-218. PubMed ID: 24292339
[TBL] [Abstract][Full Text] [Related]
27. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
Buolamwini JK; Assefa H
J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.
Lu XY; Chen YD; Jiang YJ; You QD
Eur J Med Chem; 2009 Sep; 44(9):3718-30. PubMed ID: 19428156
[TBL] [Abstract][Full Text] [Related]
29. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment.
Lu XY; Chen YD; You QD
Chem Biol Drug Des; 2010 Feb; 75(2):195-203. PubMed ID: 20028393
[TBL] [Abstract][Full Text] [Related]
30. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations.
Dong L; Feng R; Bi J; Shen S; Lu H; Zhang J
J Mol Model; 2018 Mar; 24(4):86. PubMed ID: 29511885
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening.
Nicola G; Smith CA; Lucumi E; Kuo MR; Karagyozov L; Fidock DA; Sacchettini JC; Abagyan R
Biochem Biophys Res Commun; 2007 Jul; 358(3):686-91. PubMed ID: 17509532
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
33. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.
Lu H; Tonge PJ
Biochemistry; 2010 Feb; 49(6):1281-9. PubMed ID: 20055482
[TBL] [Abstract][Full Text] [Related]
34.
Liu J; Feng K; Ren Y
J Biomol Struct Dyn; 2019 Sep; 37(14):3803-3821. PubMed ID: 30261821
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of Plasmodium falciparum enoyl-ACP reductase and implications on drug discovery.
Lindert S; McCammon JA
Protein Sci; 2012 Nov; 21(11):1734-45. PubMed ID: 22969045
[TBL] [Abstract][Full Text] [Related]
36. Diversity in enoyl-acyl carrier protein reductases.
Massengo-Tiassé RP; Cronan JE
Cell Mol Life Sci; 2009 May; 66(9):1507-17. PubMed ID: 19151923
[TBL] [Abstract][Full Text] [Related]
37. Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
Wang ZZ; Yang J; Sun XD; Ma CY; Gao QB; Ding L; Liu HM
J Biomol Struct Dyn; 2019 Aug; 37(13):3482-3495. PubMed ID: 30175693
[TBL] [Abstract][Full Text] [Related]
38. A rational approach to identify inhibitors of Mycobacterium tuberculosis enoyl acyl carrier protein reductase.
Chhabria MT; Parmar KB; Brahmkshatriya PS
Curr Pharm Des; 2013; 19(21):3878-83. PubMed ID: 23477735
[TBL] [Abstract][Full Text] [Related]
39. Structure-based drug design and in vitro testing reveal new inhibitors of enoyl-acyl carrier protein reductases.
Ghattas MA; Eissa NA; Tessaro F; Perozzo R; Scapozza L; Obaid D; Atatreh N
Chem Biol Drug Des; 2019 Aug; 94(2):1545-1555. PubMed ID: 31063658
[TBL] [Abstract][Full Text] [Related]
40. Identification of the Structural Features of Guanine Derivatives as MGMT Inhibitors Using 3D-QSAR Modeling Combined with Molecular Docking.
Sun G; Fan T; Zhang N; Ren T; Zhao L; Zhong R
Molecules; 2016 Jun; 21(7):. PubMed ID: 27347909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
